Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Scientific Reports|November 23, 2025
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus BevacizumabAndrea Dalbeni, Filippo Cattazzo, Marco Vicardi, et al.
Oncology Research|April 3, 2026
The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and DiabetesAndrea Dalbeni, Marco Vicardi, Leonardo A Natola, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2026
Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE ScoreLorenzo Canova, Eleonora Alimenti, Lorenzo Argiento, et al.
Journal of Hepatocellular Carcinoma|April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and BevacizumabBernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Journal of Cancer Research and Clinical Oncology|December 12, 2022
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world studyMara Persano, Margherita Rimini, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patientsMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 22, 2024
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumabMargherita Rimini, Bernardo Stefanini, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2022
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide populationAndrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, et al.
Liver Cancer|October 9, 2025
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse StudyAlessandro Vitale, Jung Sun Kim, Giuseppe Cabibbo, et al.
Pageof 13